Misonix Cash Flow - Quarterly (NASDAQ:MSON)

Add to My Stocks
$13.45 $0.25 (1.89%) MSON stock closing price Jun 22, 2018 (Closing)

The Misonix cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. The profit-loss statement shows Misonix profits, the balance sheet shows Misonix debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. Misonix had cash and cash equivalents of $9.04M at beginning of the quarter and $12.3M at quarter end of 2018 Q3. Misonix cash flow analysis tells whether or not the company has enough cash for its day to day activities, and for investing for future growth. MSON decrease in investments stood at a value of $-0.47M for the latest quarter 2018 Q3.

View and download details of Misonix cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jul - Jun2018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q2
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow1.04M--1.06M---1.65M1.27M-
Net Increase (Decrease) in Assets Liabilities-1.67M-1.1M-0.53M-0.62M-0.96M---1.73M-2.38M-1.21M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net7.46M8.99M-----0.25M1.09M--
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.35M-0.11M-0.08M-0.49M-0.23M-0.16M-0.1M-0.47M-0.41M-0.32M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments----------
Other Cash Inflow (Outflow) from Investment Activities-0.12M-0.05M-0.02M-0.22M-0.18M-0.15M-0.08M-0.13M-0.07M-0.04M
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares---4.33M4.3M4.14M----
Issuance (Repayment) of Debt Securities----------
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year9.04M9.62M7.03M5.8M6.27M6.88M9.9M3.41M1.87M2.9M
Cash & Equivalents at Year End12.3M12.1M10.52M11.55M11.85M12.76M8.6M9.04M8.35M9.55M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Misonix stock comparison chart provides an easy way to compare the stock price with peers along with details of Misonix stock price history.
The statement of cash flows can be categorized into the following main sections:

  • Misonix had a Net Change in Cash and Cash Equivalents of $- in the latest quarter 2018 Q3. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Misonix stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Misonix increased its cash from operating activities to $1M till 2018 Q3. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash from investing stood at a negative value of $-0.47M for MSON stock. A company with surplus cash usually thinks of re-investing it in the form of buying fixed assests, or purchasing plant/ machinery which will help grow the business further. By looking at cash flow from investment activities one can check where the company is putting its cash.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $- for Misonix.

Key Financial Ratios For Misonix Cash Flow

FCF margin

Quarterly Cash Flow Statements For Misonix, Inc. Peers

Bovie Medical cash flow, CONMED cash flow, Harvard Bioscience cash flow, Newport cash flow